Revance Therapeutics Inc
NASDAQ:RVNC

Watchlist Manager
Revance Therapeutics Inc Logo
Revance Therapeutics Inc
NASDAQ:RVNC
Watchlist
Price: 3.65 USD
Market Cap: 381m USD

Relative Value

The Relative Value of one RVNC stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.65 USD, Revance Therapeutics Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RVNC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
59
Median 3Y
1.9
Median 5Y
10.6
Industry
2.6
Forward
1.5
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3.4
Industry
21.4
Forward
-2.3
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-4.5
Industry
16.4
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-3.9
Industry
22.8
vs History
vs Industry
0
Median 3Y
-2.4
Median 5Y
-2.3
Industry
2.2
vs History
69
vs Industry
43
Median 3Y
2.7
Median 5Y
11.8
Industry
2.9
Forward
2.4
vs History
69
vs Industry
54
Median 3Y
3.9
Median 5Y
17.7
Industry
5.5
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-4.8
Industry
13
Forward
-6.1
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-4.5
Industry
16.5
Forward
-4.4
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-5.2
Industry
15.6
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-4.9
Industry
18.7
vs History
71
vs Industry
31
Median 3Y
2.8
Median 5Y
3.7
Industry
1.9

Multiples Across Competitors

RVNC Competitors Multiples
Revance Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Revance Therapeutics Inc
NASDAQ:RVNC
382.9m USD 1.6 -2.1 -3.8 -3.7
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57.3 38.6 41.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
500.7B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.6B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
221.5B GBP 5.1 31.6 108.8 159.3
CH
Novartis AG
SIX:NOVN
219.5B CHF 4.9 19.1 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
277.7B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
Revance Therapeutics Inc
NASDAQ:RVNC
Average P/E: 25.2
Negative Multiple: -2.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
57.3
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Revance Therapeutics Inc
NASDAQ:RVNC
Average EV/EBITDA: 440.2
Negative Multiple: -3.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Revance Therapeutics Inc
NASDAQ:RVNC
Average EV/EBIT: 1 883.8
Negative Multiple: -3.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.4
36%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5